Approximately 10% of people taking Ozempic or Wegovy may not experience the drugs’ full benefits due to genetic factors, according to a new study published this week. Researchers identified a condition dubbed “GLP-1 resistance” in these individuals, where their bodies produce elevated levels of the targeted hormone but fail to respond properly to it.
The findings, first reported in ScienceDaily, come as demand for GLP-1 receptor agonists has skyrocketed globally. These drugs, originally developed for type 2 diabetes, have gained FDA approval for weight management and shown promise in treating other conditions.
“This explains why we see non-responders in clinical trials,” said one metabolic researcher familiar with the study who requested anonymity because the paper hasn’t been peer-reviewed. “The genetic component suggests we might need personalized approaches for these medications.”
Analysts note the research could impact pharmaceutical development, with companies potentially screening for these variants in future trials. Some clinicians caution that lifestyle factors still play a major role in treatment outcomes.
If confirmed, the discovery may lead to genetic testing before prescribing these expensive medications. Health economists warn this could create new disparities in access to effective obesity treatments.